Abstract
Canagliflozin improves glycemic control and body weight and reduces insulin doses in patients with type 2 diabetes treated with insulin in real practice
Highlights
Canagliflozin is a class of oral anti-diabetic agent with limited real-world experience reported in patients treated with insulin
Canagliflozin administration in patients with type 2 diabetes Mellitus (T2DM) treated with insulin was associated with an improvement in glycemic control and body weight and with a reduction of insulin doses with limited and mild adverse events
Therapy combination of canagliflozin and insulin was investigated in a reported sub study of the canagliflozin Cardiovascular Assessment Study (CANVAS) [11] and other few trials [15,16,17,18,19] and it was demonstrated that the addition of canagliflozin to insulin therapy improves glycemic control and decreases weight
Summary
Canagliflozin is a class of oral anti-diabetic agent with limited real-world experience reported in patients treated with insulin. Different clinical studies report that less than 50% of the patients with type 2 diabetes Mellitus (T2DM) treated with insulin achieve adequate metabolic control goals, and at least one-quarter of the patients with T2DM treated with basal insulin have difficulties attaining the recommended HbA1c goal, despite adequate fasting plasma glucose (FPG) levels [1,2,3,4] In these patients, most of the Clinical Practice Guidelines (CPG) for diabetes [5,6] proposed bolus prandial insulin addition before one or more meals as a more effective strategy than insulin alone, but with important limiting factors such as the develop of hypoglycemia and weight gain. While clinical trials results are useful determining clinical outcomes in a representative sample of patients in controlled settings, these results
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
